(NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the ...

NeoGenomics moving toward a full U.S. clinical launch of its RaDaR ST molecular residual disease (MRD) assay in Q1 2026FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics, Inc. (NASDAQ:NEO), a leading ...

NEW YORK, May 26, 2011 /PRNewswire/ -- Signal Genetics, the parent company of Myeloma Health LLC and Respira Health LLC, a privately held predictive genetic testing company focused on oncology, ...

Emotional intelligence is increasingly required in today’s workplace. To help students and job candidates meet this demand and flourish professionally, Florida Gulf Coast University (FGCU) and ...

FT. MYERS, Fla., Oct. 23, 2018 (GLOBE NEWSWIRE) — NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, announced today that it has entered into a definitive ...

Lee County Commissioners voted this week to contribute up to $354,000 in economic incentives, on top of $1.4 million committed by the state, to foster expansion plans in the county by Fort Myers-based ...

WILMINGTON, N.C.--(BUSINESS WIRE)--Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and NeoGenomics Laboratories, Inc., a leading provider of ...

Pharmaceutical Product Development and NeoGenomics Laboratories plan to integrate their international pathology and molecular testing offerings, with NeoGenomics providing lab services for PPD’s ...

Lab is located in same building as PPD® Laboratories’ Central Lab and will support Asia-Pacific oncology trials Fully integrated with PPD’s CRO capabilities, PPD Laboratories offers bioanalytical, ...

This time it's going to China. The Fort Myers-based laboratory — specializing in genetic testing for cancer — has announced plans to grow its global footprint with the addition of a research lab in ...